Study #2021-0975
20210098; A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
MD Anderson Study Status
Not Accepting
Treatment Agent
Bemarituzumab, Nivolumab, Chemotherapy
Description
The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) and nivolumab. The main objective Part 2 is to compare efficacy of bemarituzumab plus chemotherapy (mFOLFOX6 or capecitabine combined with oxaliplatin (CAPOX)) and nivolumab to placebo plus chemotherapy (mFOLFOX6 or CAPOX) and nivolumab as assessed by overall survival.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Study phase:
Phase III
Physician name:
Jaffer Ajani
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-866-720-1940
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.